Catheter Precision, Inc. filings document material events, operating results, shareholder votes, capital-structure matters, and governance disclosures for a NYSE American-listed company. The records include 8-K reports on financial results and business updates tied to the company’s electrophysiology products, including VIVO and LockeT, as well as strategic expansion activity.
VTAK’s proxy and current-report filings also cover stockholder approval matters, common-stock issuance proposals, convertible preferred stock series, promissory note amendments, royalty-right exchanges, related-party transaction disclosures, and other material agreements. These filings frame the company’s public reporting around medical device commercialization, financing arrangements, and corporate governance.
Catheter Precision, Inc. completed the closing of a private placement of 3,470 shares of newly designated Series C-3 Convertible Preferred Stock, each with a $1,000 stated value, for aggregate gross proceeds of $3,470,000. The transaction followed prior stockholder approval and effectiveness of a Form S-1 registering resale of common shares issuable upon conversion.
The Series C-3 Preferred Stock is convertible at the holder’s option into common stock at an initial conversion price of $0.632 per share, subject to a $0.35 floor price the company may waive and customary anti-dilution adjustments. Conversion is limited by a 4.99% beneficial ownership cap, which holders may increase to 9.99% with 61 days’ notice. The preferred shares rank senior to common stock for dividends and liquidation, and conversion will dilute existing common holders. A Certificate of Designation filed on July 14, 2026 formally designated the 3,470 Series C-3 shares. Net proceeds are intended for working capital, loan repayment and general corporate purposes, with the offering relying on Section 4(a)(2) and Rule 506(b) exemptions.
Catheter Precision, Inc. is registering 68,067,042 shares of Common Stock for resale by existing holders, including shares issuable from multiple series of convertible preferred stock and warrants. The company will not receive any proceeds from these sales, though it will bear registration expenses.
The capital structure includes Series C-1, C-2, C-3, C-4 and D preferred stock with variable conversion prices tied to trading levels, a large potential Series C-4 facility, related‑party Series J preferred stock and Series M warrants, all convertible into Common Stock subject to ownership limits and floor-price conditions. As of July 10, 2026, 3,609,471 Common shares were outstanding, and the prospectus warns that full issuance of registered conversion shares could cause substantial dilution for current stockholders.
Catheter operates two segments: cardiac electrophysiology, built around its VIVO mapping system and LockeT suture retention device, and a newer private aviation platform acquired through FLYTE and Ponderosa Air, which generated approximately $0.2 million of revenue for the quarter ended March 31, 2026. The company reports limited cash, a significant working capital deficit and a going‑concern warning, and plans to use earlier private‑placement proceeds mainly to repay debt, restructure legacy catheter operations and simplify its balance sheet.
Catheter Precision, Inc. is registering 68,067,042 shares of common stock for resale by existing investors. These shares include 392,608 already outstanding shares, plus stock issuable from multiple preferred series (C-1, C-2, C-3, D, J) and Series M warrants. The company will receive no proceeds from these sales, while existing holders face very high potential dilution: as of July 2, 2026, only 3,609,471 shares were outstanding, and the prospectus notes that issuance of the covered stock could raise the share count by about 25.3 times and represent roughly 96.2% of post‑issuance shares. The filing also details heavy reliance on recent private placements, significant debt assumed in the FLYTE aviation acquisition, restrictive financing covenants, and an auditor’s substantial doubt about the company’s ability to continue as a going concern.
Catheter Precision, Inc. is registering 68,067,042 shares of common stock for resale by existing security holders, and will not receive any proceeds from these stockholder sales. As of June 22, 2026, there were 2,692,473 shares of common stock issued and outstanding.
The registered shares include common stock issued or issuable upon conversion of multiple series of preferred stock and related warrants, as well as shares tied to the acquisition of private aviation company FLYTE and related financings. The company highlights that issuing these shares could significantly increase its outstanding share count and cause substantial dilution to existing holders. The prospectus also notes liquidity pressures, assumed and new debt tied to the FLYTE acquisition, and an auditor statement expressing substantial doubt about the company’s ability to continue as a going concern.
Catheter Precision, Inc. entered a Securities Purchase Agreement to buy 2,941,176 shares of Volato Group, Inc. common stock in a private placement at $0.34 per share, for a total Subscription Amount of $1,000,000. As of June 5, 2026, the market value of these Volato securities was approximately $1,000,000.
As consideration for participating, Catheter Precision will receive certain freely tradeable equity securities of a third-party entity from Volato, which had an aggregate market value of about $1,100,000 as of June 5, 2026. Closing is subject to customary conditions, including accuracy of representations, covenant performance, and no Material Adverse Effect for Volato.
Under a related Registration Rights Agreement, Volato must file a registration statement on Form S-3 (or other appropriate form) to cover resale of the shares within 10 calendar days and use best efforts to have it declared effective under specified timing. The agreements include customary covenants, indemnities, and registration procedures.
Catheter Precision, Inc. reported first quarter 2026 results showing rapid growth and a broader business mix. Revenue for Q1 2026 rose 200% year-over-year to $432,000, up from $143,000 in Q1 2025, helped by both its core medical device business and the new Flyte aviation platform.
The medical device segment increased revenue by approximately 73%, expanded use of its VIVO and LockeT products into more hospitals, and is now present in 15 countries, backed by new clinical publications and conference presentations. The Company also completed the acquisition of Flyte, which scaled its fleet from one to three aircraft and reached a roughly $200,000 monthly revenue run rate within 22 days of post-acquisition operations.
Net loss improved markedly, narrowing to $1.7 million from $4.0 million in Q1 2025, including about $560,000 of non-cash expenses. Management highlights a dual-engine growth strategy that combines high-margin electrophysiology devices with a technology-enabled regional air mobility platform.
Catheter Precision, Inc. reported Q1 2026 results showing a larger business but continued heavy losses and tight liquidity. Revenue rose to $432,000 from $143,000, driven by growth in VIVO and LockeT product sales and the addition of private aviation services.
The company posted a net loss of $1.7 million, improved from a $4.0 million loss a year earlier, as operating loss narrowed and fair value gains on deferred consideration offset other charges. Total assets increased to $35.1 million, including $22.3 million of intangibles and $9.7 million of goodwill, largely from acquiring 100% of private aviation platform FLYTE and its subsidiary Ponderosa.
Cash and cash equivalents were only $0.4 million at March 31, 2026, with a working capital deficit of $18.5 million. Management explicitly states there is substantial doubt about the company’s ability to continue as a going concern and plans to rely on additional equity and debt financings, including recent and potential issuances of Series C and Series D preferred stock and warrant exercises, to fund operations while it builds out both the cardiac electrophysiology and private aviation segments.
Catheter Precision, Inc. notified the SEC it cannot timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 because additional time is needed to complete the non-cash accounting for its March 9, 2026 acquisitions of Fly Flyte, Inc. and Ponderosa Air, LLC. Management expects to use the 5-calendar-day extension permitted under Rule 12b-25 and anticipates filing within that period.
The notification was signed by Chief Financial Officer Philip Anderson on May 18, 2026. The filing explains the delay relates specifically to balance-sheet accounting for the acquired businesses as of the quarter end.
Catheter Precision, Inc. Schedule 13G/A amendment discloses that a group of affiliated investment entities and individuals (the "Reporting Persons") report 0% beneficial ownership of the Issuer's common stock, par value $0.0001 per share. The filing identifies the Reporting Persons, their business address, and states the shares reported were held by the Funds.